648 reports of this reaction
1.8% of all BUSULFAN reports
#13 most reported adverse reaction
ACUTE GRAFT VERSUS HOST DISEASE IN SKIN is the #13 most commonly reported adverse reaction for BUSULFAN, manufactured by Otsuka America Pharmaceutical, Inc.. There are 648 FDA adverse event reports linking BUSULFAN to ACUTE GRAFT VERSUS HOST DISEASE IN SKIN. This represents approximately 1.8% of all 36,413 adverse event reports for this drug.
Patients taking BUSULFAN who experience acute graft versus host disease in skin should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE GRAFT VERSUS HOST DISEASE IN SKIN is a less commonly reported adverse event for BUSULFAN, but still significant enough to appear in the safety profile.
In addition to acute graft versus host disease in skin, the following adverse reactions have been reported for BUSULFAN:
The following drugs have also been linked to acute graft versus host disease in skin in FDA adverse event reports:
ACUTE GRAFT VERSUS HOST DISEASE IN SKIN has been reported as an adverse event in 648 FDA reports for BUSULFAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE GRAFT VERSUS HOST DISEASE IN SKIN accounts for approximately 1.8% of all adverse event reports for BUSULFAN, making it a notable side effect.
If you experience acute graft versus host disease in skin while taking BUSULFAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.